David L. Sloman

Statistics

Publications

Citations

990

H-Index

Active since

1996

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Quantitative BioSciences

Boston University

Discovery Laboratories (United States)

Target (United States)

David L. Sloman is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicinal chemistry, drug discovery, and pharmacology.

ORCID

Publications per year

1996–2024

Publications

Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2)

Joey L. Methot, Prasun K. Chakravarty, Mélissa Chénard et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 187 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +10

A Selective Synthesis of 2,2-Difluorobicyclo[1.1.1]pentane Analogues: “BCP-F<sub>2</sub>”

Xiaoshen Ma, David L. Sloman, Yongxin Han et al. · Organic Letters · 2019 · 158 citations

Natural Sciences, Chemistry, Medicinal Chemistry +11

Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors

Qinglin Pu, Hongjun Zhang, Liangqin Guo et al. · ACS Medicinal Chemistry Letters · 2020 · 87 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Total Synthesis and Absolute Stereochemical Assignment of Kibdelone C

David L. Sloman, Jeffrey W. Bacon, John A. Porco · Journal of the American Chemical Society · 2011 · 86 citations

Natural Sciences, Chemistry, Medicinal Chemistry +16

Synthetic Studies of 2,2‐Difluorobicyclo[1.1.1]pentanes (BCP‐F<sub>2</sub>): The Scope and Limitation of Useful Building Blocks for Medicinal Chemists

Xiaoshen Ma, W.de.S.F. Pinto, Luu N. Pham et al. · European Journal of Organic Chemistry · 2020 · 54 citations

Pharmacy, Chemistry, Medicinal Chemistry +9

1–5 of 21